Expert IVIG and SCIG care for primary and secondary immune deficiency — without the hospital, without the commute, and without compromising on clinical standards

There is a particular kind of burden that comes with needing regular medical treatment. It is not just the treatment itself. It is the scheduling, the travel, the waiting rooms, the disruption to work and family, and the creeping sense that your life has been reorganised around your condition rather than the other way around.

For patients living with immune deficiency disorders, that burden is compounded by the nature of the condition itself. These are people whose immune systems cannot reliably protect them from infection. Every journey to a hospital infusion centre is a journey through a building full of the very pathogens their bodies struggle most to fight. Every crowded waiting room is a clinical risk. Every hour away from home is an hour spent managing exposure alongside the treatment that is supposed to reduce it.

Immunodeficiency infusion therapy delivered at home does not just remove the inconvenience of the clinic. It removes the contradiction at the heart of clinic-based care for immune deficiency patients — and it replaces it with a model that protects patients in every direction at once.

KabaFusion was built around that insight. Every aspect of its immunodeficiency infusion therapy programme exists to bring specialised clinical care to the patient, in the place where the patient is safest and most supported, without sacrificing a single element of the clinical rigour that immune deficiency treatment demands.

The Foundation — What Immunodeficiency Infusion Therapy Replaces

To understand why immunodeficiency infusion therapy matters so profoundly, it helps to understand what it is replacing.

The human immune system produces immunoglobulins — a class of proteins more commonly known as antibodies — that circulate through the bloodstream, identify pathogens, and neutralise them before they can establish infection. In a healthy immune system, this process runs continuously and automatically. Most people never think about it.

In patients with immune deficiency disorders, that process is compromised. The immune system either produces insufficient quantities of immunoglobulins, produces immunoglobulins that do not function correctly, or in some cases fails to produce them at all. The result is a body that cannot mount an adequate defence against infections that a healthy immune system would clear without difficulty.

The consequences accumulate over time. Recurrent pneumonias. Chronic sinus infections. Ear infections that never fully resolve. Bronchiectasis from repeated lung damage. Each infection is not just an illness — it is evidence of a gap in protection that will be there again the next time, and the time after that.

Immunodeficiency infusion therapy fills that gap. By delivering concentrated immunoglobulins — prepared from the pooled plasma of thousands of carefully screened, healthy donors — directly into the body, immunodeficiency infusion therapy provides the broad-spectrum antibody protection that the patient’s own immune system cannot maintain. The infections become less frequent. The gaps between hospitalisations widen. The quality of daily life improves in ways that are difficult to quantify but immediately and profoundly felt by the patients who experience them.

Who Immunodeficiency Infusion Therapy Serves

KabaFusion’s immunodeficiency infusion therapy programme serves patients across the full spectrum of primary and secondary immune deficiency diagnoses.

Primary Immunodeficiency

Primary immunodeficiency disorders are genetic in origin. They are present from birth, inherited through differences in the architecture of the immune system that prevent it from functioning as it should. More than 450 distinct primary immunodeficiency diseases have now been formally classified — each representing a different point of failure in the immune system’s ability to produce, deploy, or regulate its antibody response.

The conditions most frequently treated through KabaFusion’s immunodeficiency infusion therapy programme include Common Variable Immunodeficiency, X-Linked Agammaglobulinemia, Specific Antibody Deficiency, Hyper IgM Syndrome, and Selective IgA Deficiency presenting with recurrent infections. Each condition follows its own clinical pattern. Each patient’s lived experience of it is shaped by their specific diagnosis, their medical history, and the circumstances of their individual life.

Secondary Immunodeficiency

Secondary immunodeficiency disorders develop over time. They are not inherited — they are acquired, most often as a consequence of another serious illness or its treatment. Chemotherapy and radiation for cancer, long-term corticosteroid or immunosuppressive therapy, organ transplantation, and hematologic malignancies can all damage the immune system’s functional capacity in ways that create a sustained need for immunodeficiency infusion therapy.

Secondary immunodeficiency carries its own particular emotional weight. Patients living with primary immunodeficiency have often grown up managing their condition and have built coping strategies and clinical relationships around it. Patients who develop secondary immunodeficiency in adulthood are frequently navigating a new and unexpected diagnosis at a time when they are already managing the illness or treatment that caused it.

KabaFusion’s clinical team approaches both populations with the same core principle: every immunodeficiency infusion therapy patient receives a care plan built specifically for them, developed in direct collaboration with their treating immunologist, and designed to function as a natural and seamless extension of their existing medical care.

IVIG Therapy — Decades of Evidence, Delivered at Your Door

IVIG therapy is the most extensively studied and most widely used form of immunodeficiency infusion therapy in clinical practice. Its evidence base spans decades, its safety profile is well characterised, and its clinical outcomes in reducing infection frequency and improving quality of life for immune deficiency patients are thoroughly documented.

Intravenous immunoglobulin is delivered directly into the bloodstream, typically every three to four weeks, in doses calibrated to each patient’s IgG trough levels and clinical response. The interval, volume, and infusion rate are not fixed — they are managed by KabaFusion’s clinical pharmacists as a living protocol, adjusted as the patient’s clinical picture evolves and as their treating immunologist’s guidance changes over time.

Every IVIG immunodeficiency infusion session conducted by KabaFusion follows a structured clinical process. A thorough pre-infusion assessment establishes the patient’s baseline before the infusion begins. Vital signs are monitored continuously throughout. A period of careful post-infusion observation follows before the clinical team completes their session. Nothing about the care experience is abbreviated because it takes place at home. The standard is identical to what the patient would receive in a hospital infusion centre. The location is simply better.

SCIG Therapy — When Independence Is the Goal

For a significant and growing proportion of immune deficiency patients, SCIG therapy has changed the experience of immunodeficiency infusion therapy fundamentally — not by changing the clinical outcome, but by transforming who controls it.

Subcutaneous immunoglobulin therapy delivers immunoglobulins beneath the skin rather than into a vein, in smaller doses administered more frequently — typically weekly or twice weekly rather than monthly. The subcutaneous route produces steadier immunoglobulin blood levels between sessions, avoiding the peak-and-trough pattern that some patients find produces inconsistent symptom control across the monthly IVIG cycle.

The defining feature of SCIG immunodeficiency infusion therapy is self-administration. With the appropriate training and support, eligible patients learn to administer their own treatment independently — at home, on their own schedule, without the structural constraints of clinic appointments or nursing visit windows.

For patients who have spent years building their lives around treatment schedules they did not choose, the shift to self-administered SCIG immunodeficiency infusion therapy is often described as one of the most significant improvements in their daily quality of life since their diagnosis. It is not a smaller form of care. For many patients, it is a larger form of independence.

KabaFusion’s SCIG training programme is designed to make that independence feel fully earned and completely supported. Training is delivered step by step, at a pace that is genuinely comfortable for each individual patient. All required equipment and supplies are provided. A dedicated clinical pharmacist is assigned to each SCIG patient for ongoing oversight. And around-the-clock clinical availability ensures that the patient moving through their first weeks of independent self-administration is never left without someone to call — regardless of the hour and regardless of how small the question feels.

Clinical Depth That Separates KabaFusion From General Providers

The distinction between a general home infusion provider and a specialised immunodeficiency infusion therapy partner is not subtle. It is the difference between a provider that can technically administer immunoglobulins and a provider that understands immune deficiency patients well enough to anticipate their needs, manage their complexity, and optimise their outcomes over time.

KabaFusion’s clinical team — pharmacists and nurses alike — receives dedicated immunoglobulin therapy education that covers the specific clinical demands of this patient population. Rate titration protocols specific to immunoglobulin administration. Premedication strategies appropriate for patients with histories of infusion reactions. Adverse reaction recognition and management approaches calibrated to immune deficiency presentations. This is not a supplemental module added to general home infusion training. It is a distinct and rigorous clinical preparation for a patient population with distinct and serious needs.

KabaFusion maintains comprehensive longitudinal records for every immunodeficiency infusion therapy patient — tracking IgG trough levels, infusion history, infection frequency, and clinical response systematically across every session. The value of this documentation compounds over time. A patient’s clinical trajectory becomes visible. Subtle changes in response become detectable early. Dosing adjustments are informed by evidence rather than estimation.

After every immunodeficiency infusion session, KabaFusion provides the treating immunologist with a detailed clinical report covering all relevant parameters. This is not a courtesy. It is a structural commitment to the collaborative model of care that produces the best outcomes for immune deficiency patients — a model in which the home infusion specialist and the treating physician are partners in a continuous clinical conversation, not independent actors managing separate pieces of the same patient.

Insurance, Financial Access, and the Benefits Team

KabaFusion accepts Medicare, Medicaid, and most major commercial insurance plans for immunodeficiency infusion therapy. The insurance process for home-based infusion care can be genuinely complex — prior authorisations, medical necessity documentation, periodic coverage reviews, and periodic challenges from payors who do not understand the specific clinical requirements of immune deficiency patients.

KabaFusion’s dedicated benefits team takes full ownership of that complexity. Every insurance interaction is managed on behalf of the patient. Every authorisation is pursued. Every coverage challenge is addressed. The patient’s role in the insurance process is to receive care. The paperwork is KabaFusion’s responsibility.

When insurance coverage is insufficient or unavailable, KabaFusion actively connects patients with manufacturer patient assistance programmes and additional financial support resources. The commitment behind this effort is genuine and unconditional: financial circumstances should never determine whether a patient can access the immunodeficiency infusion therapy they need. This principle is not a marketing statement. It is a clinical and ethical position that shapes every decision the benefits team makes on behalf of every patient it serves.

How to Begin

Immunologists and referring physicians can initiate immunodeficiency infusion therapy with KabaFusion through a straightforward online referral process. Most patients receive their first home infusion within days of referral completion.

KabaFusion operates across all 50 states. The clinical standards, the specialised training, the pharmacist oversight, the 24-hour availability, and the personal warmth that defines the KabaFusion care experience are consistent regardless of where the patient lives.

Phone: 888.204.9304 Website: www.kabafusion.com Email: info@KabaFusion.com Referrals: kabafusion.com/easy-patient-referral-form

Care That Comes to You

Immune deficiency is a condition that asks a great deal of the people who live with it. It asks for vigilance, for planning, for the constant background management of risk that healthy people never have to think about.

Immunodeficiency infusion therapy should not add to that burden. It should reduce it — by providing reliable, expert, clinically rigorous protection in the place where the patient is safest, most comfortable, and most fully themselves.

That is the care KabaFusion delivers. And it is the care that every immune deficiency patient, in every state, deserves.